Identification of a new class of small molecule C5a receptor antagonists

https://doi.org/10.1016/j.bmcl.2009.11.058Get rights and content

Abstract

C5a is a terminal product of the complement cascade that activates and attracts inflammatory cells including granulocytes, mast cells and macrophages via a specific GPCR, the C5a receptor (C5aR). Inhibition of C5a/C5aR interaction has been shown to be efficacious in several animal models of autoimmune diseases, including RA, SLE and asthma. This account reports the discovery of a new class of C5aR antagonists through high-throughput screening. The lead compounds in this series are selective and block C5a binding, C5a-promoted calcium flux in human neutrophils with nanomolar potency.

Graphical abstract

A new class of potent and selective C5a receptor antagonists was discovered through a hit-to-lead process.

  1. Download : Download full-size image

Section snippets

Acknowledgements

We thank the CPG team and DAC group at Wyeth for their analytical supports to this project.

References and notes (29)

  • M.G. Strainic et al.

    Immunity

    (2008)
  • J. Kohl et al.

    Mol. Immunol.

    (2007)
  • H. Ji et al.

    Immunity

    (2002)
  • H. Sumichika et al.

    J. Biol. Chem.

    (2002)
  • Y. Gong et al.

    Bioorg. Med. Chem. Lett.

    (2008)
  • P.A. Ward

    Nat. Rev. Immun.

    (2004)
  • Y. Fukuoka et al.

    J. Immunol.

    (2008)
  • N.P. Gerard et al.

    Nature

    (1991)
  • H.N. Fernandez et al.

    J. Immunol.

    (1978)
  • C. Gerard et al.

    Annu. Rev. Immunol.

    (1994)
  • J.V. Ravetch

    J. Clin. Invest.

    (2002)
  • M. Idzko et al.

    J. Clin. Invest.

    (2006)
  • M. Miyamasu et al.

    J. Immunol.

    (1995)
  • E. Neumann et al.

    Arthritis Rheumat.

    (2002)
  • Cited by (0)

    View full text